Kucukbas, Gokce NazSanhal, Cem YasarUygur, Dilek2025-05-102025-05-1020211551-38151551-382310.1080/15513815.2019.16936742-s2.0-85075720334https://doi.org/10.1080/15513815.2019.1693674https://hdl.handle.net/20.500.14720/13742Sahin, Dilek/0000-0001-8567-9048; Kucukbas, Gokce Naz/0000-0002-2755-3700Background: Preeclampsia (PE) may represent an inflammatory process. Endocan (ESM-1) is a marker of endothelial inflammation. We compared plasma endocan levels between PE and control groups and between early and late-onset PE. Study design: Maternal plasma endocan levels were measured in 41 preeclampsia (PE) pregnancies - 25 early-onset (<34 weeks); 16 late-onset (>= 34 weeks), and 37 non-complicated pregnancies (22 matched with early-onset PE, 15 with late onset). Results: There was no significant differences between plasma endocan levels of patients with PE and control group (468.8(IQR: 169.7)ng/L vs 462.4(IQR: 321.1)ng/L, p > 0.05), between early and late-onset PE (458.8(221.8)ng/L vs 469.8(122.6)ng/L, p > 0.05), between early-onset PE and corresponding control group (458.8(221.8)ng/L vs 506.2(1481.9)ng/L, p > 0.05), or late-onset PE and corresponding control group (469.8(122.6)ng/L vs 451.0(85.1)ng/L, p > 0.05). Conclusion: There was no significant difference between endocan levels of early or late-onset PE compared with their corresponding control groups, nor between early and late-onset preeclampsia groups.eninfo:eu-repo/semantics/closedAccessEarly-Onset PreeclampsiaLate-Onset PreeclampsiaEndocanEsm-1Article403Q4Q221422131769346WOS:000498504300001